Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials

被引：46

作者：

Tanaka, Yoshiya ^{[1
]}

Kavanaugh, Arthur ^{[2
]}

Wicklund, Jason ^{[3
]}

McInnes, Iain B. ^{[4
]}

机构：

[1] Univ Occupat & Environm Hlth Japan, Dept Internal Med 1, Kitakyushu, Fukuoka, Japan

[2] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA

[3] Gilead Sci Inc, Foster City, CA USA

[4] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

MODERN RHEUMATOLOGY | 2022年 / 32卷 / 01期

关键词：

Filgotinib; Janus kinase; rheumatoid arthritis; safety; selectivity; SELECTIVE JAK1 INHIBITOR; IN-VITRO; GLPG0634/GS-6034; UPADACITINIB; CYTOKINES;

D O I：

10.1080/14397595.2021.1902617

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the treatment of rheumatoid arthritis (RA), Janus kinase inhibitors (jakinibs) represent an emerging class of targeted therapies in addition to biologics. The number of jakinibs has been growing and as of 2020, filgotinib was the latest jakinib to enter the international market for treating RA. Filgotinib has demonstrated preferential inhibition of JAK1-dependent cytokine signaling in in vitro assays. It has been evaluated in the DARWIN (phase 2) and FINCH (phase 3) series of clinical studies for treating patients with moderately-to-severely active RA. Filgotinib received regulatory approval in Japan and Europe in September 2020, while in August 2020 the United States Food and Drug Administration requested additional data from two ongoing clinical studies assessing the potential impact of filgotinib on sperm parameters. This article will review the pharmacological properties, efficacy, and safety of filgotinib as demonstrated in clinical studies. Expert opinion will be provided on jakinibs for RA treatment from the viewpoints of basic research and clinical practice.

引用

页码：1 / 11

页数：11

共 47 条

[1] JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future [J].

Angelini, Jacopo ;

Talotta, Rossella ;

Roncato, Rossana ;

Fornasier, Giulia ;

Barbiero, Giorgia ;

Dal Cin, Lisa ;

Brancati, Serena ;

Scaglione, Francesco .

BIOMOLECULES, 2020, 10 (07) :1-40

[2] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial [J].

Combe, Bernard ;

Kivitz, Alan ;

Tanaka, Yoshiya ;

van der Heijde, Desiree ;

Simon, J. Abraham ;

Baraf, Herbert S. B. ;

Kumar, Uma ;

Matzkies, Franziska ;

Bartok, Beatrix ;

Ye, Lei ;

Guo, Ying ;

Tasset, Chantal ;

Sundy, John S. ;

Jahreis, Angelika ;

Genovese, Mark C. ;

Mozaffarian, Neelufar ;

Landewe, Robert B. M. ;

Bae, Sang-Cheol ;

Keystone, Edward C. ;

Nash, Peter .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) :848-858

[3] The Natural History of Rheumatoid Arthritis [J].

Deane, Kevin D. ;

Holers, V. Michael .

CLINICAL THERAPEUTICS, 2019, 41 (07) :1256-1269

[4] Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition [J].

Dowty, Martin E. ;

Lin, Tsung H. ;

Jesson, Michael I. ;

Hegen, Martin ;

Martin, David A. ;

Katkade, Vaibhav ;

Menon, Sujatha ;

Telliez, Jean-Baptiste .

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (06)

[5] Upadacitinib: First Approval [J].

Duggan, Sean ;

Keam, Susan J. .

DRUGS, 2019, 79 (16) :1819-1828

[6] Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 [J].

Fridman, Jordan S. ;

Scherle, Peggy A. ;

Collins, Robert ;

Burn, Timothy C. ;

Li, Yanlong ;

Li, Jun ;

Covington, Maryanne B. ;

Thomas, Beth ;

Collier, Paul ;

Favata, Margaret F. ;

Wen, Xiaoming ;

Shi, Jack ;

McGee, Ryan ;

Haley, Patrick J. ;

Shepard, Stacey ;

Rodgers, James D. ;

Yeleswaram, Swamy ;

Hollis, Greg ;

Newton, Robert C. ;

Metcalf, Brian ;

Friedman, Steven M. ;

Vaddi, Kris .

JOURNAL OF IMMUNOLOGY, 2010, 184 (09) :5298-5307

[7]

Genovese M., 2019, ACRARP ANN M

[8] INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS [J].

Genovese, M. C. ;

Winthrop, K. ;

Tanaka, Y. ;

Takeuchi, T. ;

Kivitz, A. ;

Matzkies, F. ;

Ye, L. ;

Jiang, D. ;

Guo, Y. ;

Bartok, B. ;

Besuyen, R. ;

Burmester, G. R. ;

Gottenberg, J. E. .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 :320-321

[9] Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial [J].

Genovese, Mark C. ;

Kalunian, Kenneth ;

Gottenberg, Jacques-Eric ;

Mozaffarian, Neelufar ;

Bartok, Beatrix ;

Matzkies, Franziska ;

Gao, Jie ;

Guo, Ying ;

Tasset, Chantal ;

Sundy, John S. ;

de Vlam, Kurt ;

Walker, David ;

Takeuchi, Tsutomu .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (04) :315-325

[10]

Gilead Sciences, 2020, JYS FIL SUMM PROD IN

← 1 2 3 4 5 →